Table S2 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression

Junfeng Xu,Zeng Ye,Qifeng Zhuo,Heli Gao,Yi Qin,Xin Lou,Wuhu Zhang,Fei Wang,Yan Wang,Desheng Jing,Guixiong Fan,Yue Zhang,Xuemin Chen,Jie Chen,Xiaowu Xu,Xianjun Yu,Shunrong Ji

DOI: https://doi.org/10.1158/0008-5472.23569581.v1

2023-01-01

Abstract:Clinicopathologic parameters of 50 PanNET patients

What problem does this paper attempt to address?

Table S3 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression

Junfeng Xu,Zeng Ye,Qifeng Zhuo,Heli Gao,Yi Qin,Xin Lou,Wuhu Zhang,Fei Wang,Yan Wang,Desheng Jing,Guixiong Fan,Yue Zhang,Xuemin Chen,Jie Chen,Xiaowu Xu,Xianjun Yu,Shunrong Ji

DOI: https://doi.org/10.1158/0008-5472.23627621

2023-01-01

Abstract:Gene mutation analysis identified in 50 patients with PanNETs
Table S1 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression

Junfeng Xu,Zeng Ye,Qifeng Zhuo,Heli Gao,Yi Qin,Xin Lou,Wuhu Zhang,Fei Wang,Yan Wang,Desheng Jing,Guixiong Fan,Yue Zhang,Xuemin Chen,Jie Chen,Xiaowu Xu,Xianjun Yu,Shunrong Ji

DOI: https://doi.org/10.1158/0008-5472.23569584

2023-01-01

Abstract:Clinicopathologic parameters according to the expression of NAE1, Ubc12, Rbx1 and global NEDD8 conjugation
Data from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression

Junfeng Xu,Zeng Ye,Qifeng Zhuo,Heli Gao,Yi Qin,Xin Lou,Wuhu Zhang,Fei Wang,Yan Wang,Desheng Jing,Guixiong Fan,Yue Zhang,Xuemin Chen,Jie Chen,Xiaowu Xu,Xianjun Yu,Shunrong Ji

DOI: https://doi.org/10.1158/0008-5472.can-22-3599

IF: 11.2

2023-01-01

Cancer Research

Abstract:Abstract Pancreatic neuroendocrine tumors (PanNET) are a group of rare sporadic malignant tumors in the pancreas. MEN1 is the most frequently mutated gene in PanNETs. The MEN1-encoded protein is a typical tumor suppressor that forms a complex with epigenetic and transcription factors and is an attractive target for therapeutic interventions for patients with PanNET. A better understanding of the regulation of MEN1 protein expression in PanNETs could identify strategies for targeting MEN1. Here, we found that the neddylation pathway and DCAF7-mediated ubiquitination regulated MEN1 protein expression. Increased expression of members of the neddylation pathway and DCAF7 was found in PanNET tissues compared with paired-adjacent tissues and was associated with poor prognosis in patients with PanNET. Suppression of neddylation using the neddylation inhibitor MLN4924 or RNA interference significantly induced MEN1 accumulation and repressed cancer-related malignant phenotypes. CUL4B and DCAF7 promoted MEN1 degradation by binding and catalyzing its ubiquitination. In PanNET cells resistant to everolimus, a pharmacologic mTOR inhibitor widely used for advanced PanNET patient treatment, the downregulation of DCAF7 expression overcame resistance and synergized with everolimus to suppress mTOR activation and to inhibit cancer cell growth. The effects of DCAF7 loss could be counteracted by the simultaneous knockdown of MEN1 both in vitro and in vivo. The inverse correlation between DCAF7 and MEN1 was further validated in clinical specimens. This study revealed that the posttranslational control of MEN1 expression in PanNET is mediated by neddylation and the CUL4B–DCAF7 axis and identifies potential therapeutic targets in patients with MEN1-associated PanNET. Significance: Identification of neddylation and ubiquitination pathways that regulate MEN1 protein stability provides an opportunity for therapeutic interventions for treating patients with pancreatic neuroendocrine tumors.
MEN1 degradation induced by neddylation and the CUL4B-DCAF7 axis promotes pancreatic neuroendocrine tumor progression

Junfeng Xu,Zeng Ye,Qifeng Zhuo,Heli Gao,Yi Qin,Xin Llou,Wuhu Zhang,Fei Wang,Yan Wang,Desheng Jing,Guixiong Fan,Yue Zhang,Xuemin Chen,Jie Chen,Xiaowu Xu,Xianjun Yu,Shunrong Ji

DOI: https://doi.org/10.1158/0008-5472.can-22-3599

IF: 11.2

2023-03-22

Cancer Research

Abstract:Pancreatic neuroendocrine tumors (PanNETs) are a group of rare sporadic malignant tumors in the pancreas. MEN1 is the most frequently mutated gene in PanNETs. The MEN1-encoded protein is a typical tumor suppressor that forms a complex with epigenetic and transcription factors and is an attractive target for therapeutic interventions for PanNET patients. A better understanding of the regulation of MEN1 protein expression in PanNETs could identify strategies for targeting MEN1. Here, we found that the neddylation pathway and DCAF7-mediated ubiquitination regulated MEN1 protein expression. Increased expression of members of the neddylation pathway and DCAF7 were found in PanNET tissues compared to paired-adjacent tissues and were associated with poor prognosis in PanNET patients. Suppression of neddylation using the neddylation inhibitor MLN4924 or RNA interference significantly induced MEN1 accumulation and repressed cancer-related malignant phenotypes. CUL4B and DCAF7 promoted MEN1 degradation by binding and catalyzing its ubiquitination. In PanNET cells resistant to everolimus, a pharmacological mTOR inhibitor widely used for advanced PanNET patient treatment, the downregulation of DCAF7 expression overcame resistance and synergized with everolimus to suppress mTOR activation and inhibit cancer cell growth. The effects of DCAF7 loss could be counteracted by the simultaneous knockdown of MEN1 both in vitro and in vivo. The inverse correlation between DCAF7 and MEN1 was further validated in clinical specimens. This study revealed that the posttranslational control of MEN1 expression in PanNET is mediated by neddylation and the CUL4B-DCAF7 axis and identifies potential therapeutic targets in MEN1-associated PanNET patients.

oncology
Figure S1 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression

Junfeng Xu,Zeng Ye,Qifeng Zhuo,Heli Gao,Yi Qin,Xin Lou,Wuhu Zhang,Fei Wang,Yan Wang,Desheng Jing,Guixiong Fan,Yue Zhang,Xuemin Chen,Jie Chen,Xiaowu Xu,Xianjun Yu,Shunrong Ji

DOI: https://doi.org/10.1158/0008-5472.23627633

2023-01-01

Abstract:Representative tandem MS spectrum of the LPENYTDETWQK peptide from CUL4B as determined by IP-Mass Spec
Combined deletion of MEN1, ATRX and PTEN triggers development of high-grade pancreatic neuroendocrine tumors in mice

Mary Esmeralda Fuentes,Xiaoyin Lu,Natasha M. Flores,Simone Hausmann,Pawel K. Mazur

DOI: https://doi.org/10.1038/s41598-024-58874-2

IF: 4.6

2024-04-14

Scientific Reports

Abstract:Pancreatic neuroendocrine tumors (PanNETs) are a heterogeneous group of tumors that exhibit an unpredictable and broad spectrum of clinical presentations and biological aggressiveness. Surgical resection is still the only curative therapeutic option for localized PanNET, but the majority of patients are diagnosed at an advanced and metastatic stage with limited therapeutic options. Key factors limiting the development of new therapeutics are the extensive heterogeneity of PanNETs and the lack of appropriate clinically relevant models. In that context, genomic sequencing of human PanNETs revealed recurrent mutations and structural alterations in several tumor suppressors. Here, we demonstrated that combined loss of MEN1, ATRX, and PTEN, tumor suppressors commonly mutated in human PanNETs, triggers the development of high-grade pancreatic neuroendocrine tumors in mice. Histopathological evaluation and gene expression analyses of the developed tumors confirm the presence of PanNET hallmarks and significant overlap in gene expression patterns found in human disease. Thus, we postulate that the presented novel genetically defined mouse model is the first clinically relevant immunocompetent high-grade PanNET mouse model.

multidisciplinary sciences
MEN1 Deficiency-Driven Activation of the β-Catenin-MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance

Junfeng Xu,Xin Lou,Fei Wang,Wuhu Zhang,Xiaowu Xu,Zeng Ye,Qifeng Zhuo,Yan Wang,Desheng Jing,Guixiong Fan,Xuemin Chen,Yue Zhang,Chenjie Zhou,Jie Chen,Yi Qin,Xianjun Yu,Shunrong Ji

DOI: https://doi.org/10.1002/advs.202308417

Abstract:O6-methylguanine DNA methyltransferase (MGMT) removes alkyl adducts from the guanine O6 position (O6-MG) and repairs DNA damage. High MGMT expression results in poor response to temozolomide (TMZ). However, the biological importance of MGMT and the mechanism underlying its high expression in pancreatic neuroendocrine tumors (PanNETs) remain elusive. Here, it is found that MGMT expression is highly elevated in PanNET tissues compared with paired normal tissues and negatively associated with progression-free survival (PFS) time in patients with PanNETs. Knocking out MGMT inhibits cancer cell growth in vitro and in vivo. Ectopic MEN1 expression suppresses MGMT transcription in a manner that depends on β-Catenin nuclear export and degradation. The Leucine 267 residue of MEN1 is crucial for regulating β-Catenin-MGMT axis activation and chemosensitivity to TMZ. Interference with β-Catenin re-sensitizes tumor cells to TMZ and significantly reduces the cytotoxic effects of high-dose TMZ treatment, and MGMT overexpression counteracts the effects of β-Catenin deficiency. This study reveals the biological importance of MGMT and a new mechanism by which MEN1 deficiency regulates its expression, thus providing a potential combinational strategy for treating patients with TMZ-resistant PanNETs.
MEN1 promotes ferroptosis by inhibiting mTOR-SCD1 axis in pancreatic neuroendocrine tumors

Zeng Ye,Haidi Chen,Shunrong Ji,Yuheng Hu,Xin Lou,Wuhu Zhang,Desheng Jing,Guixiong Fan,Yue Zhang,Xuemin Chen,Qifeng Zhuo,Jie Chen,Xiaowu Xu,Xianjun Yu,Jin Xu,Yi Qin,Heli Gao

DOI: https://doi.org/10.3724/abbs.2022162

2022-11-25

Abstract:Pancreatic neuroendocrine tumor (pNET) is the second most common malignant tumors of the pancreas. Multiple endocrine neoplasia 1 ( MEN1) is the most frequently mutated gene in pNETs and MEN1-encoded protein, menin, is a scaffold protein that interacts with transcription factors and chromatin-modifying proteins to regulate various signaling pathways. However, the role of MEN1 in lipid metabolism has not been studied in pNETs. In this study, we perform targeted metabolomics analysis and find that MEN1 promotes the generation and oxidation of polyunsaturated fat acids (PUFAs). Meanwhile lipid peroxidation is a hallmark of ferroptosis, and we confirm that MEN1 promotes ferroptosis by inhibiting the activation of mTOR signaling which is the central hub of metabolism. We show that stearoyl-coA desaturase (SCD1) is the downstream of MEN1-mTOR signaling and oleic acid (OA), a metabolite of SCD1, recues the lipid peroxidation caused by MEN1 overexpression. The negative correlation between MEN1 and SCD1 is further verified in clinical specimens. Furthermore, we find that BON-1 and QGP-1 cells with MEN1 overexpression are more sensitive to everolimus, a widely used drug in pNETs that targets mTOR signaling. In addition, combined use everolimus with ferroptosis inducer, RSL3, possesses a more powerful ability to kill cells, which may provide a new strategy for the comprehensive therapy of pNETs.
Whole-Genome Landscape of Pancreatic Neuroendocrine Tumours

Aldo Scarpa,David K. Chang,Katia Nones,Vincenzo Corbo,Ann-Marie Patch,Peter Bailey,Rita T. Lawlor,Amber L. Johns,David K. Miller,Andrea Mafficini,Borislav Rusev,Maria Scardoni,Davide Antonello,Stefano Barbi,Katarzyna O. Sikora,Sara Cingarlini,Caterina Vicentini,Skye McKay,Michael C. J. Quinn,Timothy J. C. Bruxner,Angelika N. Christ,Ivon Harliwong,Senel Idrisoglu,Suzanne McLean,Craig Nourse,Ehsan Nourbakhsh,Peter J. Wilson,Matthew J. Anderson,J. Lynn Fink,Felicity Newell,Nick Waddell,Oliver Holmes,Stephen H. Kazakoff,Conrad Leonard,Scott Wood,Qinying Xu,Shivashankar Hiriyur Nagaraj,Eliana Amato,Irene Dalai,Samantha Bersani,Ivana Cataldo,Angelo P. Dei Tos,Paola Capelli,Maria Vittoria Davì,Luca Landoni,Anna Malpaga,Marco Miotto,Vicki L. J. Whitehall,Barbara A. Leggett,Janelle L. Harris,Jonathan Harris,Marc D. Jones,Jeremy Humphris,Lorraine A. Chantrill,Venessa Chin,Adnan M. Nagrial,Marina Pajic,Christopher J. Scarlett,Andreia Pinho,Ilse Rooman,Christopher Toon,Jianmin Wu,Mark Pinese,Mark Cowley,Andrew Barbour,Amanda Mawson,Emily S. Humphrey,Emily K. Colvin,Angela Chou,Jessica A. Lovell,Nigel B. Jamieson,Fraser Duthie,Marie-Claude Gingras,William E. Fisher,Rebecca A. Dagg,Loretta M. S. Lau,Michael Lee,Hilda A. Pickett,Roger R. Reddel,Jaswinder S. Samra,James G. Kench,Neil D. Merrett,Krishna Epari,Nam Q. Nguyen,Nikolajs Zeps,Massimo Falconi,Michele Simbolo,Giovanni Butturini,George Van Buren,Stefano Partelli,Matteo Fassan,Kum,Anthony J. Gill,David A. Wheeler,Richard A. Gibbs,Elizabeth A. Musgrove,Claudio Bassi,Giampaolo Tortora,Paolo Pederzoli,John V. Pearson,Nicola Waddell,Andrew V. Biankin,Sean M. Grimmond

DOI: https://doi.org/10.1038/nature21063

IF: 64.8

2017-01-01

Nature

Abstract:Neuroendocrine tumours (NETs) may arise throughout the body and are a highly heterogeneous, relatively rare class of neoplasms difficult to study also for the lack of disease models. Despite this, knowledge on their molecular alterations has expanded in the latest years, also building from genetic syndromes causing their onset. Pancreatic NETs (PanNETs) have been among the most studied, and research so far has outlined a series of recurring features, as inactivation of MEN1, VHL, TSC1/2 genes and hyperactivation of the PI3K/mTOR pathway. Next-generation sequencing has added new information by showing the key role of alternative lengthening of telomeres, driven in a fraction of PanNETs by inactivation of ATRX/DAXX. Despite this accumulation of knowledge, single studies often relied on few cases or were limited to the DNA, RNA, protein or epigenetic level with lack of integrative analysis. The International Cancer Genome Consortium aimed at removing these barriers through a strict process of data and samples collection, to produce whole-genome integrated analyses for many tumour types. The results of this effort on PanNETs have been recently published and, while confirming previous observations provide a first snapshot of how heterogeneous is the combination of genetic alterations that drive this tumour type, yet converging into four pathways whose alteration has been enriched by newly discovered mechanisms. While calling for further integration of genetic and epigenetic analyses, these data allow to reconcile previous findings in a defined frame and may provide clinical research with markers for patients stratification and to guide targeted therapy decisions.
Two well-differentiated pancreatic neuroendocrine tumor mouse models

Chung Wong,Laura H. Tang,Christian Davidson,Evan Vosburgh,Wenjin Chen,David J. Foran,Daniel A. Notterman,Arnold J. Levine,Eugenia Y. Xu

DOI: https://doi.org/10.1038/s41418-019-0355-0

IF: 12.067

2019-06-03

Cell Death and Differentiation

Abstract:Multiple endocrine neoplasia type 1 (MEN1) is a genetic syndrome in which patients develop neuroendocrine tumors (NETs), including pancreatic neuroendocrine tumors (PanNETs). The prolonged latency of tumor development in MEN1 patients suggests a likelihood that other mutations cooperate with Men1 to induce PanNETs. We propose that Pten loss combined with Men1 loss accelerates tumorigenesis. To test this, we developed two genetically engineered mouse models (GEMMs)—MPR (Men1flox/flox Ptenflox/flox RIP-Cre) and MPM (Men1flox/flox Ptenflox/flox MIP-Cre) using the Cre-LoxP system with insulin-specific biallelic inactivation of Men1 and Pten. Cre in the MPR mouse model was driven by the transgenic rat insulin 2 promoter while in the MPM mouse model was driven by the knock-in mouse insulin 1 promoter. Both mouse models developed well-differentiated (WD) G1/G2 PanNETs at a much shorter latency than Men1 or Pten single deletion alone and exhibited histopathology of human MEN1-like tumor. The MPR model, additionally, developed pituitary neuroendocrine tumors (PitNETs) in the same mouse at a much shorter latency than Men1 or Pten single deletion alone as well. Our data also demonstrate that Pten plays a role in NE tumorigenesis in pancreas and pituitary. Treatment with the mTOR inhibitor rapamycin delayed the growth of PanNETs in both MPR and MPM mice, as well as the growth of PitNETs, resulting in prolonged survival in MPR mice. Our MPR and MPM mouse models are the first to underscore the cooperative roles of Men1 and Pten in cancer, particularly neuroendocrine cancer. The early onset of WD PanNETs mimicking the human counterpart in MPR and MPM mice at 7 weeks provides an effective platform for evaluating therapeutic opportunities for NETs through targeting the MENIN-mediated and PI3K/AKT/mTOR signaling pathways.

cell biology,biochemistry & molecular biology
Molecular biology of pancreatic neuroendocrine tumors: From mechanism to translation

Xiaofei Shen,Xingzhou Wang,Xiaofeng Lu,Yang Zhao,Wenxian Guan

DOI: https://doi.org/10.3389/fonc.2022.967071

IF: 4.7

2022-09-28

Frontiers in Oncology

Abstract:Pancreatic neuroendocrine tumors (pNETs) are a group of heterogeneous tumors originated from progenitor cells. As these tumors are predominantly non-functional, most of them display asymptomatic characteristics, making it difficult to be realized from early onset. Therefore, patients with pNETs are usually diagnosed with metastatic disease or at a late disease stage. The relatively low incidence also limits our understanding of the biological background of pNETs, which largely impair the development of new effective drugs. The fact that up to 10% of pNETs develop in patients with genetic syndromes have promoted researchers to focus on the gene mutations and driver mutations in MEN1 , DAXX / ATRX and mTOR signaling pathway genes have been implicated in disease development and progression. Recent advances in sequencing technologies have further enriched our knowledge of the complex molecular landscape of pNETs, pointing out crucial roles of genes in DNA damage pathways, chromosomal and telomere alterations and epigenetic dysregulation. These novel findings may not only benefit early diagnosis of pNETs, but also help to uncover tumor heterogeneity and shape the future of translational medical treatment. In this review, we focus on the current molecular biology of pNETs and decipher how these findings may translate into future development of targeted therapy.

oncology
Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

Alfred S.L. Cheng,Suki S. Lau,Yangchao Chen,Yutaka Kondo,May S. Li,Hai Feng,Arthur K. Ching,Kin F. Cheung,Hoi K. Wong,Joanna H. Tong,Hongchuan Jin,Kwong W. Choy,Jun Yu,Ka F. To,Nathalie Wong,Tim H.-M. Huang,Joseph J.Y. Sung

DOI: https://doi.org/10.1158/0008-5472.22395236.v1

2023-01-01

Abstract:Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis
Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor

Rene Quevedo,Anna Spreafico,Jeff Bruce,Arnavaz Danesh,Samah El Ghamrasni,Amanda Giesler,Youstina Hanna,Cherry Have,Tiantian Li,S. Y. Cindy Yang,Tong Zhang,Sylvia L. Asa,Benjamin Haibe-Kains,Monika Krzyzanowska,Adam C. Smith,Simron Singh,Lillian L. Siu,Trevor J. Pugh

DOI: https://doi.org/10.1186/s13073-020-00730-9

IF: 15.266

2020-04-28

Genome Medicine

Abstract:Abstract Background Pancreatic neuroendocrine tumors (PANETs) are rare, slow growing cancers that often present with local and distant metastasis upon detection. PANETS contain distinct karyotypes, epigenetic dysregulation, and recurrent mutations in MEN1 , ATRX , and DAXX ( MAD+ ); however, the molecular basis of disease progression remains uncharacterized. Methods We evaluated associations between aneuploidy and the MAD+ mutational state of 532 PANETs from 11 published genomic studies and 19 new cases using a combination of exome, targeted panel, shallow WGS, or RNA-seq. We mapped the molecular timing of MAD+ PANET progression using cellular fractions corrected for inferred tumor content. Results In 287 PANETs with mutational data, MAD+ tumors always exhibited a highly recurrent signature of loss of heterozygosity (LOH) and copy-number alterations affecting 11 chromosomes, typically followed by genome doubling upon metastasis. These LOH chromosomes substantially overlap with those that undergo non-random mis-segregation due to ectopic CENP-A localization to flanking centromeric regions in DAXX -depleted cell lines. Using expression data from 122 PANETs, we found decreased gene expression in the regions immediately adjacent to the centromere in MAD+ PANETs. Using 43 PANETs from AACR GENIE, we inferred this signature to be preceded by mutations in MEN1 , ATRX , and DAXX . We conducted a meta-analysis on 226 PANETs from 8 CGH studies to show an association of this signature with metastatic incidence. Our study shows that MAD+ tumors are a genetically diverse and aggressive subtype of PANETs that display extensive chromosomal loss after MAD+ mutation, which is followed by genome doubling. Conclusions We propose an evolutionary model for a subset of aggressive PANETs that is initiated by mutation of MEN1 , ATRX , and DAXX , resulting in defects in centromere cohesion from ectopic CENP-A deposition that leads to selective loss of chromosomes and the LOH phenotype seen in late-stage metastatic PANETs. These insights aid in disease risk stratification and nominate potential therapeutic vulnerabilities to treat this disease.

genetics & heredity
Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor

Laura M. Williamson,Michael Steel,Jasleen K. Grewal,My Lihn Thibodeau,Eric Y. Zhao,Jonathan M. Loree,Kevin C. Yang,Sharon M. Gorski,Andrew J. Mungall,Karen L. Mungall,Richard A. Moore,Marco A. Marra,Janessa Laskin,Daniel J. Renouf,David F. Schaeffer,Steven J.M. Jones

DOI: https://doi.org/10.1101/mcs.a003814

2019-06-01

Molecular Case Studies

Abstract:Pancreatic neuroendocrine neoplasms (PanNENs) represent a minority of pancreatic neoplasms that exhibit variability in prognosis. Ongoing mutational analyses of PanNENs have found recurrent abnormalities in chromatin remodeling genes (e.g., DAXX and ATRX ), and mTOR pathway genes (e.g., TSC2 , PTEN PIK3CA , and MEN1 ), some of which have relevance to patients with related familial syndromes. Most recently, grade 3 PanNENs have been divided into two groups based on differentiation, creating a new group of well-differentiated grade 3 neuroendocrine tumors (PanNETs) that have had a limited whole-genome level characterization to date. In a patient with a metastatic well-differentiated grade 3 PanNET, our study utilized whole-genome sequencing of liver metastases for the comparative analysis and detection of single-nucleotide variants, insertions and deletions, structural variants, and copy-number variants, with their biologic relevance confirmed by RNA sequencing. We found that this tumor most notably exhibited a TSC1 -disrupting fusion, showed a novel CHD7–BEND2 fusion, and lacked any somatic variants in ATRX , DAXX , and MEN1 .

English Else
Clinical Features Of Patients With Pancreatic Neuroendocrine Neoplasms: A Retrospective Analysis Of 61 Cases In A Cancer Center

Panpan Zhang,Ming Lu,Xicheng Wang,Lin Shen,Jian Li,Jun Zhou,Xiaotian Zhang,Zhi Peng,Yanshuo Cao,Zuyao Yang,Jie Li

2017-01-01

Abstract:Objective: To assess the clinicopathological features of patients with pancreatic neuroendocrine neoplasms (pNENs) in relation with clinical outcomes. Methods: A total of 61 patients with pNENs were enrolled in this study. Patients' characteristics, treatment procedures, and clinical follow-up were retrospectively analyzed. Results: Among the 61 patients, 29 patients (47.5%) were men and 32 patients (52.5%) were women. 6 patients (9.8%) had functional pNENs and presented with diarrhea, flushing, sweating, palpitations or glucose abnormalities. At diagnosis, 31.1% (19/61) had a localized disease, 6.6% (4/61) presented with regional spread including lymph node metastases and/or extrapancreatic organ invasions, and 62.3% (38/61) had distant metastases. Liver was the most common site of metastasis. 58 cases were recorded with detailed pathological information, among which 42 patients (72.4%) were diagnosed as NET G1/G2, 16 patients (27.6%) were diagnosed as NEC G3. The chromogranin A (CgA) levels were elevated in the serum of patients with liver metastasis, unresectable tumors or a Ki-67 proliferative index >= 20%. The univariate analysis suggested that the WHO classification, stage, occurrence of liver metastasis and operative approaches were closely related to the prognosis of pNENs; while sex, age, tumor size and functional status were not. Conclusion: The pNENs are a heterogeneous group of neoplasms with diverse clinical manifestations and prognosis. Serum CgA is an indicator of tumor burden and proliferation. The WHO classification, stage, liver metastasis and operative approaches might closely relate to the prognosis of pNENs.
[The Diagnosis and Treatment of Pancreatic Neuroendocrine Neoplasms].

Ren-Chao Zhang,Yi-Ping Mou,Xiao-Wu Xu,Jia-Fei Yan,Qi-Long Chen

DOI: https://doi.org/10.3760/cma.j.issn.0529-5815.2013.09.004

2013-01-01

Abstract:OBJECTIVE:To analyze the prognostic factors of pancreatic neuroendocrine neoplasms (PNEN).METHODS:Clinical data of 61 patients with PNEN from March 1992 to December 2012 was retrospectively analyzed. There were 23 male and 38 female patients, with a median age of 52 years (ranged from 22 to 68 years). Forty-one patients were non-functional tumors, and 20 patients were functional tumors. Fifty-nine patients received operation, 13 (22.0%) patients underwent laparoscopic operation, 2 patients underwent puncture biopsy under CT guidance. Survival was analyzed with the Kaplan-Meier method.RESULTS:Among these patients, 53 (86.9%) patients underwent curative resection. The cases of grade G1, G2, G3 were 41 (67.2%), 9 (14.8%), 11 (18.0%), respectively. The cases of stageI, II, III, IV were 47 (77.0%), 7 (11.5%), 2 (3.3%), 5 (8.2%), respectively. Liver metastasis, neural invasion were found in 5 cases (8.2%), 5 cases (8.2%), respectively. The median follow-up period was 40 months (ranged from 3 to 209 months). The overall 1-, 3-, 5-year survival rates were 92.0%, 89.7%, 86.3%, respectively. Univariate analysis showed WHO classification (χ(2) = 18.503), TNM staging system (χ(2) = 23.401), liver metastasis (χ(2) = 18.606), neural invasion (χ(2) = 10.091), resection status (χ(2) = 25.514) were prognostic factors of PNEN (all P = 0.000).CONCLUSIONS:Surgical resection in PNEN results in long-term survival. WHO classification, TNM staging, resection status are effective in predicting the prognosis of PNEN. Liver metastasis, neural invasion predicted poor prognosis.
Recent Research Hotspots in Sequencing and the Pancreatic Neuroendocrine Tumor Microenvironment.

Junfeng Xu,Wuhu Zhang,Xin Lou,Zeng Ye,Yi Qin,Jie Chen,Xiaowu Xu,Xianjun Yu,Shunrong Ji

DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0284

2023-01-01

Cancer Biology and Medicine

Abstract:Multiple endocrine neoplasia 1 (MEN1) syndrome, a disease arising from a genetic predisposition to tumor development caused by MEN1 loss-of-function mutations, is characterized by the combined occurrence of neuroendocrine tumors in multiple human organs. With advances in diagnostic technologies and improvements in living standards, the detection rate of sporadic pancreatic neuroendocrine tumors (PanNETs) has recently increased. Clinical research and treatment approaches for PanNETs have made remarkable progress. However, the heterogeneity and the mechanisms underlying PanNET malignancy have not yet been fully elucidated. Recurrence and metastasis remain major issues faced by clinicians. In-depth research on the biological behavior of PanNETs is necessary to improve treatment efficacy and precision. With molecular biology advances, new basic research findings may have potential clinical translational value for PanNETs 1,2 . Specifically, advances in high-throughput sequencing technologies have greatly
The Evolutionary History of Metastatic Pancreatic Neuroendocrine Tumours Reveals a Therapy Driven Route to High-Grade Transformation

Samuel Backman,Johan Botling,Helena Nord,Suman Ghosal,Peter Stålberg,C. Christofer Juhlin,Jonas Almlöf,Anders Sundin,Liang Zhang,Lotte Moens,Barbro Eriksson,Staffan Welin,Per Hellman,Britt Skogseid,Karel Pacak,Kazhan Mollazadegan,Tobias Åkerström,Joakim Crona

DOI: https://doi.org/10.1101/2024.01.08.24300723

2024-01-10

Abstract:Tumour evolution with acquisition of more aggressive disease characteristics is a hallmark of disseminated cancer. Metastatic pancreatic neuroendocrine tumours (PanNETs) in particular, show frequent progression from a low/intermediate to a high-grade disease. To understand the molecular mechanisms underlying this phenomenon, we performed multi-omics analysis of 32 longitudinal samples from six metastatic PanNET patients. Following MEN1 inactivation, PanNETs exhibit genetic heterogeneity on both spatial and temporal dimensions with parallel and convergent tumuor evolution involving the and mTOR pathways. Following alkylating chemotherapy treatment, some PanNETs develop mismatch repair deficiency and acquire a hypermutator phenotype. This DNA hypermutation phenotype was only found in cases that also showed transformation into a high-grade PanNET. Overall, our findings contribute to broaden the understanding of metastatic PanNET, and suggests that therapy driven disease evolution is an important hallmark of this disease.

Oncology
Genomic Dissection of Gastrointestinal and Lung Neuroendocrine Neoplasm.

Haixing Wang,Li Sun,Hua Bao,Ao Wang,Panpan Zhang,Xue Wu,Xiaoling Tong,Xiaonan Wang,Jie Luo,Lin Shen,Yang W. Shao,Ming Lu

DOI: https://doi.org/10.21147/j.issn.1000-9604.2019.06.08

2019-01-01

Abstract:Objective: Neuroendocrine neoplasms (NENs) are relatively rare and heterogeneous malignancies with two major subtypes: low-grade neuroendocrine tumor (NET) and high-grade neuroendocrine carcinoma (NEC). Comprehensive molecular characterization of NENs is needed to refine our understanding of the biological underpinnings of different NEN subtypes and to predict disease progression more accurately. Methods: We performed whole-exome sequencing (WES) of NEN samples from 49 patients (25 NETs and 24 NECs) arising from the stomach, intestines or lung. Clinicopathologic features were assessed and associated with molecular events. Results: NENs generally harbor a low mutation burden, with TP53 being the top mutated gene found in 31% of patients. Consistent with other studies, p53 signaling pathway dysfunction is significantly enriched in NECs compared to NETs (P<0.01). Other than TP53, tissue type-specific mutation profiles of NENs were observed in our cohort compared to those reported in pancreatic NETs. Importantly, we observed significant genomic instability, with increased copy number alterations observed across the NEN genome, which was more profound in NECs and independently correlated with poor overall survival (OS) (P<0.001). NECs could be further stratified into two molecular subtypes based on OS (P<0.001) and the chromosomal instability score (CIS). Interestingly, we discovered that the gain of whole chromosome 5 occurred at the early stage of NEN development, followed by the loss of 5q exclusively in NECs (P<0.001). Conclusions: These findings provide novel insights into the molecular characteristics of NENs and highlight the association of genomic stability with clinical outcomes.
Epidemiological investigation of neuroendocrine differentiation in carcinomas: Focus on pancreatic and cholangiocarcinoma cohorts.

Yaru Wen,Susheng Shi

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e16375

IF: 45.3

2024-06-01

Journal of Clinical Oncology

Abstract:e16375 Background: Neuroendocrine differentiated (NED) occurs in various non-neuroendocrine organs and is associated with unique clinical profiles, disease progression, and poorer prognosis. However, global research on NED is scarce. To address this, our study utilized standardized detection methods to explore NED's prevalence in several solid tumors. This research aims to clarify NED pathological characteristics and prognostic significance, enhancing diagnostic and treatment approaches in clinical practice. Methods: Patients (18-75 years) with cancers including pancreatic, cholangiocarcinoma, gastric, colorectal, lung, breast, and prostate, were analyzed post-surgery at our hospital (January 2017- June 2018). Criteria for inclusion were normal organ function and no pre-surgery neoadjuvant therapy. Tumors were staged postoperatively using AJCC 8th criteria (stages I-III), followed by standard adjuvant chemotherapy. NED markers like Chromogranin A, Synaptophysin, and CD56 were detected in tumors via immunohistochemical staining. Results: Between January 2017 and June 2018, over 450 cases were enrolled. Initial analysis included 46 pancreatic cancer and 49 cholangiocarcinoma samples. NED markers were found in 11 (23.9%) of the pancreatic cancer patients, comprising 5 Syno (+), 10 ChrA (+), and 1 CD56 (+) cases. In cholangiocarcinoma patients, 12 (24.5%) expressed NED markers, including 4 Syno (+) and 11 ChrA (+) cases. Conclusions: This study reveals a significant occurrence of neuroendocrine differentiation in pancreatic cancer and cholangiocarcinoma. The notable prevalence of NED underscores its potential as a reference for tailoring clinical treatments. The association between NED and patient prognosis warrants further investigation.

oncology

Table S2 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression

Table S3 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression

Table S1 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression

Data from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression

MEN1 degradation induced by neddylation and the CUL4B-DCAF7 axis promotes pancreatic neuroendocrine tumor progression

Figure S1 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression

Combined deletion of MEN1, ATRX and PTEN triggers development of high-grade pancreatic neuroendocrine tumors in mice

MEN1 Deficiency-Driven Activation of the β-Catenin-MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance

MEN1 promotes ferroptosis by inhibiting mTOR-SCD1 axis in pancreatic neuroendocrine tumors

Whole-Genome Landscape of Pancreatic Neuroendocrine Tumours

Two well-differentiated pancreatic neuroendocrine tumor mouse models

Molecular biology of pancreatic neuroendocrine tumors: From mechanism to translation

Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor

Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor

Clinical Features Of Patients With Pancreatic Neuroendocrine Neoplasms: A Retrospective Analysis Of 61 Cases In A Cancer Center

[The Diagnosis and Treatment of Pancreatic Neuroendocrine Neoplasms].

Recent Research Hotspots in Sequencing and the Pancreatic Neuroendocrine Tumor Microenvironment.

The Evolutionary History of Metastatic Pancreatic Neuroendocrine Tumours Reveals a Therapy Driven Route to High-Grade Transformation

Genomic Dissection of Gastrointestinal and Lung Neuroendocrine Neoplasm.

Epidemiological investigation of neuroendocrine differentiation in carcinomas: Focus on pancreatic and cholangiocarcinoma cohorts.